These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 12199616)

  • 21. Priorities for CMV vaccine development.
    Krause PR; Bialek SR; Boppana SB; Griffiths PD; Laughlin CA; Ljungman P; Mocarski ES; Pass RF; Read JS; Schleiss MR; Plotkin SA
    Vaccine; 2013 Dec; 32(1):4-10. PubMed ID: 24129123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of vaccine strategies against congenital CMV infection in the guinea pig model.
    Schleiss MR
    J Clin Virol; 2008 Mar; 41(3):224-30. PubMed ID: 18060834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccines for cytomegalovirus.
    Bernstein DI
    Infect Disord Drug Targets; 2011 Oct; 11(5):514-25. PubMed ID: 22309618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection.
    Schleiss MR
    J Pediatr; 2007 Dec; 151(6):564-70. PubMed ID: 18035130
    [No Abstract]   [Full Text] [Related]  

  • 25. Vaccination against the human cytomegalovirus.
    Plotkin SA; Boppana SB
    Vaccine; 2019 Nov; 37(50):7437-7442. PubMed ID: 29622379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.
    Roark HK; Jenks JA; Permar SR; Schleiss MR
    J Infect Dis; 2020 Mar; 221(Suppl 1):S60-S73. PubMed ID: 32134481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology, pathogenesis and prevention of congenital cytomegalovirus infection.
    Burny W; Liesnard C; Donner C; Marchant A
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):881-94. PubMed ID: 15566332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modelling immunization strategies with cytomegalovirus vaccine candidates.
    Azevedo RS; Amaku M
    Epidemiol Infect; 2011 Dec; 139(12):1818-26. PubMed ID: 21396147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.
    John S; Yuzhakov O; Woods A; Deterling J; Hassett K; Shaw CA; Ciaramella G
    Vaccine; 2018 Mar; 36(12):1689-1699. PubMed ID: 29456015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
    Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
    J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on the current status of cytomegalovirus vaccines.
    Sung H; Schleiss MR
    Expert Rev Vaccines; 2010 Nov; 9(11):1303-14. PubMed ID: 21087108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against Congenital CMV Infection Conferred by MVA-Vectored Subunit Vaccines Extends to a Second Pregnancy after Maternal Challenge with a Heterologous, Novel Strain Variant.
    Fernández-Alarcón C; Buchholz G; Contreras H; Wussow F; Nguyen J; Diamond DJ; Schleiss MR
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection.
    Cardin RD; Bravo FJ; Pullum DA; Orlinger K; Watson EM; Aspoeck A; Fuhrmann G; Guirakhoo F; Monath T; Bernstein DI
    Vaccine; 2016 Apr; 34(17):1993-9. PubMed ID: 26973071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus.
    Dempsey AF; Pangborn HM; Prosser LA
    Vaccine; 2012 Jun; 30(27):4060-6. PubMed ID: 22525796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59).
    Marshall BC; Adler SP
    Viral Immunol; 2003; 16(4):491-500. PubMed ID: 14733736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Live Olfactory Mouse Cytomegalovirus Vaccine, Attenuated for Systemic Spread, Protects against Superinfection.
    Farrell HE; Bruce K; Stevenson PG
    J Virol; 2021 Oct; 95(21):e0126421. PubMed ID: 34431701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection.
    Lanzieri TM; Bialek SR; Ortega-Sanchez IR; Gambhir M
    Vaccine; 2014 Jun; 32(30):3780-6. PubMed ID: 24837782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dynamic transmission model with age-dependent infectiousness and reactivation for cytomegalovirus in the United States: Potential impact of vaccination strategies on congenital infection.
    Hogea C; Dieussaert I; Van Effelterre T; Guignard A; Mols J
    Hum Vaccin Immunother; 2015; 11(7):1788-802. PubMed ID: 25984886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translational mini-review series on infectious disease: congenital cytomegalovirus infection: 50 years on.
    Hassan J; Connell J
    Clin Exp Immunol; 2007 Aug; 149(2):205-10. PubMed ID: 17635529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress toward an elusive goal: current status of cytomegalovirus vaccines.
    Schleiss MR; Heineman TC
    Expert Rev Vaccines; 2005 Jun; 4(3):381-406. PubMed ID: 16026251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.